-- 
Bioline Rises Most in Week on Neuropathic Pain Treatment License

-- B y   S u s a n   L e r n e r
-- 
2011-09-07T07:46:24Z

-- http://www.bloomberg.com/news/2011-09-07/bioline-rises-most-in-week-on-neuropathic-pain-treatment-license.html
Bioline Rx Ltd. (BLRX)  rose the most in
almost a week after the biopharmaceutical company signed a
license agreement with Ramot at  Tel Aviv  University Ltd. for its
BL-7050 treatment for neuropathic and inflammatory pain.  The shares jumped 5.1 percent, the biggest intraday
increase since Sept. 1., to 1.27 shekels at 10:20 a.m. in Tel
Aviv, giving the Jerusalem-based company a market value of 157.2
million shekels ($42.9 million).  To contact the reporter on this story:
Susan Lerner in Jerusalem at 
 slerner2@bloomberg.net   To contact the editor responsible for this story:
Claudia Maedler at 
 cmaedler@bloomberg.net  